Literature DB >> 24747834

Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives.

Nora D Volkow1, Dardo Tomasi2, Gene-Jack Wang2, Yana Studentsova2, Brad Margus3, Thomas O Crawford4.   

Abstract

Ataxia-telangiectasia is a recessive genetic disorder (ATM is the mutated gene) of childhood with severe motor impairments and whereas homozygotes manifest the disorder, heterozygotes are asymptomatic. Structural brain imaging and post-mortem studies in individuals with ataxia-telangiectasia have reported cerebellar atrophy; but abnormalities of motor control characteristic of extrapyramidal dysfunction suggest impairment of broader motor networks. Here, we investigated possible dysfunction in other brain areas in individuals with ataxia-telangiectasia and tested for brain changes in asymptomatic relatives to assess if heterozygocity affects brain function. We used positron emission tomography and (18)F-fluorodeoxyglucose to measure brain glucose metabolism (quantified as µmol/100 g/min), which serves as a marker of brain function, in 10 adults with ataxia-telangiectasia, 19 non-affected adult relatives (12 siblings, seven parents) and 29 age-matched healthy controls. Statistical parametric mapping and region of interest analyses were used to compare individuals with ataxia-telangiectasia, asymptomatic relatives, and unrelated controls. We found that participants with ataxia-telangiectasia had lower metabolism in cerebellar hemispheres (14%, P < 0.001), anterior vermis (40%, P < 0.001) and fusiform gyrus (20%, P < 0.001) compared with controls or siblings, and lower metabolism in hippocampus (12%, P = 0.05) compared with controls, and showed significant intersubject variability (decreases in vermis ranged from 18% to 60%). Participants with ataxia-telangiectasia also had higher metabolism in globus pallidus (16%, P = 0.05), which correlated negatively with motor performance. Asymptomatic relatives had lower metabolism in anterior vermis (12%; P = 0.01) and hippocampus (19%; P = 0.002) than controls. Our results indicate that, in addition to the expected decrease in cerebellar metabolism, participants with ataxia-telangiectasia had widespread changes in metabolic rates including hyperactivity in globus pallidus indicative of basal ganglia involvement. Changes in basal ganglia metabolism offer potential insight into targeting strategies for therapeutic deep brain stimulation. Our finding of decreased metabolism in vermis and hippocampus of asymptomatic relatives suggests that heterozygocity influences the function of these brain regions. Published by Oxford University Press on behalf of the Guarantors of Brain 2014. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  ATM; ataxia telangiectasia mutated; cerebellum; fusiform gyrus; globus pallidus; hippocampus

Mesh:

Substances:

Year:  2014        PMID: 24747834      PMCID: PMC4032102          DOI: 10.1093/brain/awu092

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

Review 1.  Contrasting connectivity of the ventralis intermedius and ventralis oralis posterior nuclei of the motor thalamus demonstrated by probabilistic tractography.

Authors:  Jonathan A Hyam; Sarah L F Owen; Morten L Kringelbach; Ned Jenkinson; John F Stein; Alexander L Green; Tipu Z Aziz
Journal:  Neurosurgery       Date:  2012-01       Impact factor: 4.654

Review 2.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation.

Authors:  Alfonso Fasano; Antonio Daniele; Alberto Albanese
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

3.  On the architecture of the posterior zone of the cerebellum.

Authors:  Hassan Marzban; Richard Hawkes
Journal:  Cerebellum       Date:  2011-09       Impact factor: 3.847

4.  Neuropathology in classical and variant ataxia-telangiectasia.

Authors:  Mijke M M Verhagen; Jean-Jacques Martin; Marcel van Deuren; Chantal Ceuterick-de Groote; Corry M R Weemaes; Berry H P H Kremer; Malcolm A R Taylor; Michèl A A P Willemsen; Martin Lammens
Journal:  Neuropathology       Date:  2011-10-24       Impact factor: 1.906

5.  Cerebral abnormalities in adults with ataxia-telangiectasia.

Authors:  D D M Lin; P B Barker; H M Lederman; T O Crawford
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-25       Impact factor: 3.825

6.  Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients.

Authors:  A Li; M Swift
Journal:  Am J Med Genet       Date:  2000-05-29

7.  Quantitative neurologic assessment of ataxia-telangiectasia.

Authors:  T O Crawford; A S Mandir; M A Lefton-Greif; S N Goodman; B K Goodman; H Sengul; H M Lederman
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

8.  Cytoplasmic ATM in neurons modulates synaptic function.

Authors:  Jiali Li; Yu R Han; Mark R Plummer; Karl Herrup
Journal:  Curr Biol       Date:  2009-12-03       Impact factor: 10.834

9.  Brain MRI abnormalities in ataxia-telangiectasia.

Authors:  Mario Habek; Vesna V Brinar; Marko Rados; Ivana Zadro; Kamelija Zarković
Journal:  Neurologist       Date:  2008-05       Impact factor: 1.398

10.  fMRI activities in the emotional cerebellum: a preference for negative stimuli and goal-directed behavior.

Authors:  Caroline K L Schraa-Tam; Willem J R Rietdijk; Willem J M I Verbeke; Roeland C Dietvorst; Wouter E van den Berg; Richard P Bagozzi; Chris I De Zeeuw
Journal:  Cerebellum       Date:  2012-03       Impact factor: 3.847

View more
  12 in total

1.  Trihexyphenidyl for treatment of dystonia in ataxia telangiectasia: a case report.

Authors:  Liping Zhang; Yu Jia; Xiaohong Qi; Mingyu Li; Shiyu Wang; Yuping Wang
Journal:  Childs Nerv Syst       Date:  2019-11-05       Impact factor: 1.475

Review 2.  DNA repair abnormalities leading to ataxia: shared neurological phenotypes and risk factors.

Authors:  Edward C Gilmore
Journal:  Neurogenetics       Date:  2014-07-20       Impact factor: 2.660

Review 3.  More Than Ataxia: Hyperkinetic Movement Disorders in Childhood Autosomal Recessive Ataxia Syndromes.

Authors:  Toni S Pearson
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-07-16

Review 4.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

5.  The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment.

Authors:  Jianmin Chen; Yanping Chen; Graham Vail; Heiman Chow; Yang Zhang; Lauren Louie; Jiali Li; Ronald P Hart; Mark R Plummer; Karl Herrup
Journal:  Mol Neurodegener       Date:  2016-08-18       Impact factor: 14.195

Review 6.  Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer.

Authors:  Erika S Dahl; Katherine M Aird
Journal:  Front Oncol       Date:  2017-11-29       Impact factor: 6.244

7.  Voxel-based meta-analysis of gray and white matter volume abnormalities in spinocerebellar ataxia type 2.

Authors:  Qing Han; Jing Yang; Hai Xiong; Huifang Shang
Journal:  Brain Behav       Date:  2018-08-20       Impact factor: 2.708

Review 8.  Movement Disorders in Genetic Pediatric Ataxias.

Authors:  Simone Gana; Enza Maria Valente
Journal:  Mov Disord Clin Pract       Date:  2020-04-06

9.  Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.

Authors:  Olivia E Rowe; D Rangaprakash; Akila Weerasekera; Neha Godbole; Elizabeth Haxton; Peter F James; Christopher D Stephen; Robert L Barry; Florian S Eichler; Eva-Maria Ratai
Journal:  Mol Genet Metab       Date:  2021-06-24       Impact factor: 4.204

10.  Motor pathway degeneration in young ataxia telangiectasia patients: A diffusion tractography study.

Authors:  Ishani Sahama; Kate Sinclair; Simona Fiori; James Doecke; Kerstin Pannek; Lee Reid; Martin Lavin; Stephen Rose
Journal:  Neuroimage Clin       Date:  2015-08-20       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.